Behring works

from Wikipedia, the free encyclopedia
Fritz Gehrke : Illustration around 1905
Marburg-Marbach location
Marburg-Görzhausen location

The Behringwerke are a former pharmaceutical company in Marburg , which existed from 1904 to 1997. Today the Behringwerke are an important biotechnology group in which many well-known companies in the industry are represented.

Foundation and history

Emil von Behring , who became a professor at the Philipps University of Marburg in 1895 , received the Nobel Prize in 1901 for his development of serum therapy against diphtheria . With the prize money he financed the establishment of a pharmaceutical factory to manufacture the serum. After his first laboratory at the castle became too small and because the city of Marburg could not provide him with suitable land, he founded the Behring-Werk oHG in 1904. In 1913 he was able to buy an old brickworks in neighboring Marbach , the later location of the company.

Under the direction of Albert Demnitz , the Behringwerke participated as part of IG Farbenindustrie from 1942 in cooperation with the Hygiene Institute of the Waffen-SS in typhus experiments on prisoners in Buchenwald concentration camp .

After the IG Farbenindustrie was dissolved, the Behringwerke became part of Hoechst AG in 1952 .

In 1967 a new virus broke out in the laboratories, which was named after the city of Marburg virus . The virus was introduced by monkeys from Uganda, who were imported for vaccine production .

Conversion into an industrial park

From 1997 the Behringwerke, like the entire Hoechst AG, were divided into various individual companies and sold or merged (see also CSL Behring , Siemens Healthineers , GlaxoSmithKline , Novartis , Dade Behring , Sanofi-Aventis , Pharmaserv ).

This is implemented according to the operating concept of an industrial park , with Pharmaserv GmbH, as the operating company of the Marbach and Görzhausen I works, providing the infrastructure (roads and parking spaces, supply lines, data center , logistics center, plant fire brigade , rental space). For services that are not provided by the operating company (e.g. canteen operations), various other service providers have settled on the factory premises (including Provadis and Consortium Gastronomie GmbH).

Hoechst AG had previously sold various divisions and outsourced site operations to specially founded companies at locations where various companies subsequently worked (see, among others, Infraserv Höchst , InfraServ Wiesbaden , InfraServ Gendorf , InfraServ Knapsack ). In the previous cases, the company shares of the site operator were distributed to the respective "founding members" of the respective industrial park. The location of the former Behringwerke in Marburg was sold to private individuals in 2005 by the Hoechst successor Sanofi-Aventis as part of a management buyout . According to its own statement, the Behringwerke site operator is the only independent site operator in Germany.

Development as an industrial park

Due to the growth of the individual site participants, various investments have been made at the site, which also result in its expansion. The construction of the third part of the "Mars Campus" ("Marburg location") by Novartis, which opened in 2014 after investments of € 240 million, should be emphasized. This part of the factory operates under the name of Görzhausen II at the city of Marburg and is operated by the pharmaceutical company itself. The new owner GlaxoSmithKline is currently expanding this part of the plant with new production facilities (planned volume: € 162 million) and the expansion of the logistics center. In the meantime, however, new products are being sought for parts of the factory section, as the rights to the vaccines that are mainly produced have been sold by the GSK Group to Bavarian Nordic and the Group wants to set up its own production within five years.

Within the Görzhausen location, CSL Behring is currently building a new plant for basic fractionation, which will replace the plant currently in the main plant in Marbach from the end of 2022 and deliver four times the volume. In addition, further processing steps are to be carried out in the new building in a second project. The company puts the total investment at € 547 million.

In addition, it was announced at the end of 2018 that the site operator Pharmaserv CSL Behring will rent out another office building that has yet to be built for 700 employees. In this building, the employees distributed across many small office buildings are to be consolidated. The company CSL Behring is also aiming for the research and development laboratories and has therefore been building a new laboratory building for approx. 600 employees at the Görzhausen site since November 2019.

Due to the current growth, the city is examining additional options for expanding the location. To this end, the development plans for the Görzhausen plant section were initially adapted and the number of floor areas (by 100%) and the number of building masses (by 60% and 100%) significantly increased.

With a new "master plan" of the city, the framework conditions for further growth and, in perspective, the foundations for the "Görzhausen III" section are to be laid. In particular, this involves expanding the infrastructure to connect the site (transport / public transport, supply of water, electricity, gas and data networks). By order of the regional council, the expansion of the plant fire brigade had already been implemented beforehand, so that in addition to the volunteers there are 6 full-time workers on a 24-hour basis.

In Marburg, Marbach and Görzhausen currently (November 2019) around 6,000 people work across 16 companies.

Current companies at the location

The following is a list of the largest companies in the area. There are also other service providers.

Turnover figures are taken from the Federal Gazette , provided they are given for the location . Unless otherwise documented, the number of employees comes from an information brochure from the training service provider Provadis.

Companies Product / service Employee Sales (€ million)
CSL Behring Medicines for clotting disorders 2900 2,081
GlaxoSmithKline Vaccines (e.g. TBE , rabies, tetanus) 1000
Siemens Healthineers Laboratory diagnostics v. a. for hemostasis and plasma proteins approx. 1300
Infrareal (Pharmaserv) Site operation 452 approx. 92.9
Novartis Biosimilars 250

Significance for the city of Marburg

The successor companies of the Behringwerke are not only among the city's largest employers, alongside the university and the clinic , but are also the largest taxpayers. In the years 2015 to 2018, an average of 80% of the city's trade tax income (approx. 90 million euros) came from the location.

The companies also play an important role in sponsoring the local sports clubs. Site operator Pharmaserv is the name sponsor of BC Pharmaserv Marburg , which provides teams for the DBBL and WNBL , among others . Another important sponsor of the club is CSL Behring, who is also a sponsor of the Marburg Mercenaries ( GFL ).

swell

  1. ↑ On the search for traces ( Memento of the original from April 12, 2016 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. @1@ 2Template: Webachiv / IABot / www.mrlife.de
  2. ^ Derek S. Linton: Emil Von Behring: Infectious Disease, Immunology, Serum Therapy . American Philosophical Society, 2005, ISBN 978-0-87169-255-9 , pp. 297-298.
  3. ↑ Killer Viruses: Leaping the Niche . In: Der Spiegel . No. 2 , 1995 ( online ).
  4. ^ Hoechst AG: The smashing. In: CHEM Manager. March 15, 2008, accessed November 24, 2019 .
  5. ↑ a b factory homepage
  6. ↑ Infraereal wants to stir up the market as an independent location operator group. January 22, 2008, accessed November 24, 2019 .
  7. ↑ Gesa Coordes: Vaccine from Mars. In: Ärztezeitung. June 6, 2014, accessed May 1, 2018 .
  8. ↑ Groundbreaking ceremony in Marburg: GSK invests 162 million euros. In: pharma-food.de. March 22, 2017, accessed May 1, 2018 .
  9. ↑ 10 million infrastructure investment for warehouse expansion on the MARS * campus of GSK. In: de.gsk.com. April 25, 2018, accessed May 1, 2018 .
  10. ↑ Bavarian Nordic takes over Rabipur and Encepur from GSK. October 21, 2019, accessed on November 18, 2019 (German).
  11. ↑ GSK sells two vaccines. Retrieved November 18, 2019 .
  12. ↑ Behring building takes shape. In: Ärztezeitung. March 27, 2018, accessed May 1, 2018 .
  13. ↑ CSL Behring wins the contract for “Sphinx”. Retrieved November 18, 2019 .
  14. ↑ Pharmaserv builds new headquarters for CSL Behring at the Marburg location -. December 12, 2018, accessed on January 20, 2019 (German).
  15. ↑ Millions invested in Marburg. Retrieved November 18, 2019 .
  16. ↑ Commercial development planning for the city of Marburg. City of Marburg, 2017, pp. 73–76 , accessed on May 1, 2018 .
  17. ^ City of Marburg: 1. Change to the development plan No. 26/4 . ( marburg.de [accessed October 20, 2018]).
  18. ^ City of Marburg: 2nd amendment to the development plan No. 26/4 . ( marburg.de [accessed October 20, 2018]).
  19. ↑ Template - VO / 7297/2020 - Behring site master plan. Retrieved June 6, 2020 .
  20. ↑ Training at the Behringwerke site in Marburg 2020. Provadis, accessed on December 22, 2019 .
  21. ↑ CSL Behring - well equipped for the future. Pharmaserv, accessed March 3, 2019 .
  22. ↑ New master plan for industrial park. Retrieved June 6, 2020 .

Web links

Commons : Behringwerke  - collection of images, videos and audio files
Commons : Görzhausen (Marburg)  - Collection of images, videos and audio files